Affordable Access

deepdyve-link
Publisher Website

Nanobodies targeting mouse/human VCAM1 for the nuclear imaging of atherosclerotic lesions.

Authors
  • Broisat, Alexis
  • Hernot, Sophie
  • Toczek, Jakub
  • De Vos, Jens
  • Riou, Laurent M
  • Martin, Sandrine
  • Ahmadi, Mitra
  • Thielens, Nicole
  • Wernery, Ulrich
  • Caveliers, Vicky
  • Muyldermans, Serge
  • Lahoutte, Tony
  • Fagret, Daniel
  • Ghezzi, Catherine
  • Devoogdt, Nick
Type
Published Article
Journal
Circulation Research
Publisher
Ovid Technologies (Wolters Kluwer Health)
Publication Date
Mar 30, 2012
Volume
110
Issue
7
Pages
927–937
Identifiers
DOI: 10.1161/CIRCRESAHA.112.265140
PMID: 22461363
Source
Medline
License
Unknown

Abstract

The (99m)Tc-labeled, anti-VCAM1 nanobody cAbVCAM1-5 allowed noninvasive detection of VCAM1 expression and displayed mouse and human cross-reactivity. Therefore, this study demonstrates the potential of nanobodies as a new class of radiotracers for cardiovascular applications. The nanobody technology might evolve into an important research tool for targeted imaging of atherosclerotic lesions and has the potential for fast clinical translation.

Report this publication

Statistics

Seen <100 times